Thursday, April 19, 2018 – This week the Food and Drug Administration (FDA) approved targeted therapy drug, osimertinib (Tagrisso), as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors with the EGFR mutations. The approval is based off results from a study showing that Tagrisso as a first-line treatment prevented the cancer from progressing for 8.7 months longer than erlotinib (Tarceva) and gefitinib (Iressa).

Up until this point, Tagrisso was approved as a second-line treatment given to NSCLC patients with a certain EGFR mutation.

Click here for the full press release.